According to
Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best drug store stocks to buy right now are:
1. High Tide (NASDAQ:HITI)
High Tide (NASDAQ:HITI) is the #1 top pharmaceutical retailer stock out of 8 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year.
Learn more.
The Component Grade breakdown for High Tide (NASDAQ:HITI) is: Value: C, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: C, and AI: C.
High Tide (NASDAQ:HITI) has a Due Diligence Score of 46, which is 23 points higher than the pharmaceutical retailer industry average of 23.
HITI passed 15 out of 33 due diligence checks and has strong fundamentals. High Tide has seen its stock return 1.5% over the past year, overperforming other pharmaceutical retailer stocks by 47 percentage points.
High Tide has an average 1 year
price target of $6.13, an upside of 126.85% from High Tide's current stock price of $2.70.
High Tide stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 2 analysts covering High Tide, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
2. Pomdoctor (NASDAQ:POM)
Pomdoctor (NASDAQ:POM) is the #2 top pharmaceutical retailer stock out of 8 with a Zen Rating of C. Stocks with a rating of C have had an average return of +7.53% per year.
Learn more.
The Component Grade breakdown for Pomdoctor (NASDAQ:POM) is: Value: C, Growth: C, Momentum: C, Sentiment: C, Safety: C, Financials: C, and AI: C.
Pomdoctor (NASDAQ:POM) has a Due Diligence Score of 10, which is -13 points lower than the pharmaceutical retailer industry average of 23.
POM passed 3 out of 33 due diligence checks and has weak fundamentals.
3. Scienture Holdings (NASDAQ:SCNX)
The Component Grade breakdown for Scienture Holdings (NASDAQ:SCNX) is: Value: D, Growth: A, Momentum: D, Sentiment: C, Safety: F, Financials: D, and AI: F.
Scienture Holdings (NASDAQ:SCNX) has a Due Diligence Score of 12, which is -11 points lower than the pharmaceutical retailer industry average of 23.
SCNX passed 4 out of 33 due diligence checks and has weak fundamentals. Scienture Holdings has seen its stock lose -91.93% over the past year, underperforming other pharmaceutical retailer stocks by -47 percentage points.